OneChain Immunotherapeutics

onechaintx.com ↗ ·Barcelona ·Pre-Series A

OneChain Immunotherapeutics is a clinical-stage biotech company in Barcelona developing CAR-T cell therapies for haematological cancers, spun out in June 2020 from the Josep Carreras Leukaemia Research Institute and ICREA based on research led by Dr. Pablo Menéndez. Its lead asset OC-1 targets CD1a in cortical T-cell acute lymphoblastic leukaemia (first patient dosed in the CARxALL trial at Hospital Clínic and Hospital Sant Joan de Déu; FDA Orphan Drug designation), alongside a CD22 programme and in vivo CAR-T work via a collaboration with NanoCell Therapeutics. It raised a €6.7M pre-Series A in 2023 led by Invivo Capital and is part of a consortium awarded a €3.8M grant for AI-designed targeted viral particles.

Founded

2020

Founders

Total funds raised

€9.8M

SectorsBiotech, Immuno-oncology, CAR-T cell therapy, Healthtech & Bio, Deeptech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Jorge Alemany

Co-founder and former CEO (2020–2024)

Pablo Menéndez

Founder, President and Chief Scientific Officer

Global models 5

Allogene Therapeutics

United States · www.allogene.com ↗

Clinical-stage biotech developing CAR-T cell therapies for blood cancers, funded by venture capital before its IPO, like OneChain.

$400MComparable

Umoja Biopharma

United States · www.umoja-biopharma.com ↗

Venture-backed biotech developing in vivo CAR-T therapies for cancer, the same approach as OneChain's in vivo CAR-T programme.

$360MComparable

Juno Therapeutics

United States

Academic spin-out that raised large venture rounds to take CD19 CAR-T therapies for leukaemia and lymphoma into the clinic, the path OneChain is following.

$310MComparable

Cargo Therapeutics

United States · www.cargo-tx.com ↗

Clinical-stage, VC-funded CAR-T company targeting haematological cancers (CD22 CAR-T in lymphoma), which overlaps with OneChain's CD22 programme.

$300MComparable